LWCFA
BPMC

Loring Wolcott & Coolidge Fiduciary Advisors’s Blueprint Medicines BPMC Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-21
Closed -$2K – 725
2021
Q3 		$2K Hold
21
– – ﹤0.01% 700
2021
Q2 		$2K Buy
+21
New +$1.92K ﹤0.01% 838

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's BPMC Position: Q4 2021 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Blueprint Medicines (BPMC) in Q4 2021, closing a stake of 21 shares — an estimated $2K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in BPMC in Q2 2021 and held it in 2 quarters. The position peaked at $2K in Q3 2021. 280 funds tracked by Wall St. Rank hold BPMC as of Q4 2021.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Blueprint Medicines position as of Q4 2021 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 21 Blueprint Medicines shares in Q4 2021, an estimated $2K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Blueprint Medicines in Q2 2021 and held it in 2 quarters.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Blueprint Medicines position peaked at $2K in Q3 2021.
  • 280 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2021.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.